Report: medical affairs a 'constant presence' in Ph IV studies

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/Szepy)
(Image: iStock/Szepy)

Related tags: Clinical trial

As Phase IV studies are ‘undergoing a revolution,’ a recent report suggests that medical affairs teams are apt to head post-marketing study strategy.

The study, recently published​ by pharmaceutical business intelligence firm Cutting Edge Information, explained that this is due to their experience with physicians and medical information groups.

(Image: Cutting Edge Information)
(Image: Cutting Edge Information)

According to the report, the medical affairs team is one of the most involved in Phase IV study development. Of the Ph IV teams surveyed as part of the reserach, 75% reported that medical affairs functions remain “a constant presence during post-marketing execution​.”

Additionally, 93% of medical affairs teams are involved in the strategic planning process for Ph IV studies, according to the report – although only 68% participate in the study execution process.

Phase IV studies are undergoing a revolution​,” Natalie DeMasi, Research Team Leader at Cutting Edge Information, told us.

Notably, she explained that Phase IV studies are no longer seen as optional.

The need to collect health economic outcomes is one high priority reason why postmarketing studies are becoming more popular​,” DeMasi said. “Phase IV studies have become crucial for earning product reimbursement and market share​.”

Collecting ‘true real-world data’

The goal of a Ph IV study is to refine the understating of a medication in the real-world. However, through the research, DeMasi said the company was surprised to learn that that there is some debate on whether sponsor companies should provide the product to patients who participate in prospective observational studies. 

By definition, drug manufacturers should not have any influence on study participants throughout observational trials. Trial teams should allow clinicians and patients to make the best treatment decisions​,” she explained.

According to the report, some drug companies feel they must offer their product, as healthcare systems don’t always want to provide or reimburse the drug. However, as DeMasi explained, contributing to the treatment plan in this way could impact study outcomes.

Essentially, providing the treatment option is an intervention — more aligned with a traditional clinical trial​,” she said, “and by providing the product, that action classifies the study as an interventional trial and no longer qualifies as collecting true real-world data​.”

Related topics: Clinical Development, Phase III-IV

Related news

Show more

Related products

show more

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 26-Jul-2021 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 15-Jul-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

How a clinical metadata repository helps with data

How a clinical metadata repository helps with data

Formedix | 22-Mar-2021 | Technical / White Paper

This article covers the various ways a clinical metadata repository helps with data quality, and in turn, with data quality in the clinical trials process....

Related suppliers

Follow us

Products

View more

Webinars